Deals
Now that Acucela and Otsuka Pharmaceutical of Japan have torn up their collaborative deal to develop emixustat, which failed to meet its primary endpoint in…
Read More
Despite what some see as consolidation among drug and device companies in ophthalmology, a number of factors continue to drive innovation – from unmet needs…
Read More
FDA Approves Avedro Corneal Collagen Cross-linking Platform The US Food and Drug Administration finally gave a green light to Avedro Inc. for its KXL System,…
Read More
Now that Pfizer and Allergan have mutually agreed to terminate their proposed merger, Allergan CEO Brent Saunders told analysts Wednesday morning that the company is…
Read More
Regeneron, Bayer Join to Develop Combined Therapy Regeneron Pharmaceuticals and Bayer announced an agreement to jointly develop a combination therapy of the angiopoietin2 (Ang2) antibody…
Read MoreWith Transcend, Alcon Gains a Foothold in Glaucoma Device Market Contributed by Larry Haimovitch and Richard Mark Kirkner With its move to acquire Transcend Medical…
Read More
Putting Brakes on IPO, Apellis Lines Up Private Funding As the stock market took its 2016 nosedive, geographic atrophy drug developer Apellis Pharmaceuticals joined the…
Read More
Presbyopia, the age-related loss of accommodation and near/reading vision, typically begins at about age 40 and affects nearly everyone over age 50. This huge opportunity…
Read More
SAN FRANCISCO — Thanks to a pending boom in minimally invasive glaucoma surgery (MIGS) devices, the global glaucoma device market is poised to come out…
Read More
With the planned combination of Pfizer and Allergan to create the world’s largest pharmaceutical company, Brent Saunders, a key player in two significant acquisitions of…
Read MoreAuris Surgical Robotics Inc., a Bay Area medical technology company that had been developing a robotic platform for cataract surgery, just raised $150 million, but…
Read More
Last week’s sale of Aquesys represented a homecoming for CEO Ron Bache, who started his surgical device career at Allergan in the late 1990s. However,…
Read More
SUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.
![OIS-ANTERIOR-NEW-DATE-750x420[4300]](https://ois.net/wp-content/uploads/2020/03/OIS-ANTERIOR-NEW-DATE-750x4204300.jpg "OIS-ANTERIOR-NEW-DATE-750x420[4300]")